CLINICAL TRIALS PROFILE FOR RAPIVAB
✉ Email this page to a colleague
All Clinical Trials for RAPIVAB
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02609399 ↗ | ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir | Completed | Department of Health and Human Services | Phase 4 | 2015-11-01 | This pilot study is designed to demonstrate the feasibility of utilizing Emergency Departments (EDs) as a primary site for subject enrollment in clinical trials evaluating influenza therapeutics, and to provide pilot data for future clinical trial design and planning. Primary Objective: To prospectively enroll high-risk subjects with laboratory-confirmed influenza into a randomized, open label study of oral versus IV influenza therapeutic to include symptom evaluation and outcome assessments. Secondary Objective 1: To identify influenza positive patients utilizing a previously established triage-based assessment and rapid testing algorithm for suspected influenza infection. Secondary Objective 2: To retrospectively evaluate all potentially eligible patients for potential enrollment biases. Secondary Objective 3: To create a repository of residual nasopharyngeal samples collected from ED patients with suspected influenza illness. |
| NCT02609399 ↗ | ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir | Completed | Johns Hopkins University | Phase 4 | 2015-11-01 | This pilot study is designed to demonstrate the feasibility of utilizing Emergency Departments (EDs) as a primary site for subject enrollment in clinical trials evaluating influenza therapeutics, and to provide pilot data for future clinical trial design and planning. Primary Objective: To prospectively enroll high-risk subjects with laboratory-confirmed influenza into a randomized, open label study of oral versus IV influenza therapeutic to include symptom evaluation and outcome assessments. Secondary Objective 1: To identify influenza positive patients utilizing a previously established triage-based assessment and rapid testing algorithm for suspected influenza infection. Secondary Objective 2: To retrospectively evaluate all potentially eligible patients for potential enrollment biases. Secondary Objective 3: To create a repository of residual nasopharyngeal samples collected from ED patients with suspected influenza illness. |
| NCT02635724 ↗ | Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza | Completed | BioCryst Pharmaceuticals | Phase 3 | 2015-12-01 | This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications. All subjects will receive IV peramivir. |
| NCT05648448 ↗ | ADaptive ASsessment of TReatments for influenzA: A Phase 2 Platform Trial of Antiviral Pharmacodynamics in Early Symptomatic Influenza | Not yet recruiting | University of Oxford | Phase 2 | 2022-12-22 | This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other. AD ASTRA study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RAPIVAB
Condition Name
Clinical Trial Locations for RAPIVAB
Trials by Country
Clinical Trial Progress for RAPIVAB
Clinical Trial Phase
Clinical Trial Sponsors for RAPIVAB
Sponsor Name
